Tumors with non-V600BRAF mutations, compared with tumors with V600BRAF mutations, were found in patients who had fewer high-grade tumors (13% vs. 64%, respectively) or right-sided primary tumors (36% vs. 81%, respectively); the median overall survival was significantly longer in patients with non-V600BRAF mutations compared with those with both V600BRAF mutations and WT BRAF metastatic colorectal cancer (60.7 vs. 11.4 vs. 43 months, respectively). Here, BRAF is linked to metastatic colorectal cancer.